NCT06127602 · University of Illinois at Chicago
The REACTplusNMES Trial: A Double-blinded RCT
(REACT+NMES)
What this study is about
The aim of this study is to compare the effectiveness of 6-weeks of reactive balance training (REACT) with and without neuromuscular electrical stimulation (NMES) to paretic lower limb muscles on biomechanical, clinical, neuromuscular and neuroplastic outcomes of reactive balance control. This project is a Phase-I study and incorporates a double-blinded, randomly assigned controlled trial design.
View original scientific description
The aim of this study is to compare the effectiveness of 6-weeks of reactive balance training (REACT) with and without neuromuscular electrical stimulation (NMES) to paretic lower limb muscles on biomechanical, clinical, neuromuscular and neuroplastic outcomes of reactive balance control. This project is a Phase-I study and incorporates a double-blinded, randomized controlled trial design. Methods: Forty-six individuals with chronic stroke will be recruited and screened for determining their eligibility for the study. Once enrolled, they will be randomized into either of the two groups: intervention group (23 participants) and control group (23 participants). Both groups will undergo series of pre-training assessments which includes a postural disturbance in the form of a slip- or trip-like perturbations and walking tests in laboratory environment. After the pre-training assessment, individuals will undergo 6-weeks of training (2 hour per session, 2 sessions per week). The intervention group will receive NMES with the REACT training and the control group will receive ShamNMES. NMES will be applied to the different muscle groups of the paretic lower limb using an advanced software which is able to synchronize muscle activation with the time of perturbation onset and according to the phases of gait. After training, both groups will again be tested on all the assessments performed pre training. This study will help us understand the immediate therapeutic and mechanistic effects of REACT+NMES and inform stroke rehabilitation research and clinical practice. Our study will provide foundational evidence for future use of NMES to implement clinically applicable neuromodulation adjuvants to reactive balance training, which could be leveraged for designing more effective future interventions for fall-risk reduction.
Interventions
BEHAVIORAL
Reactive balance training with Neuromuscular Electrical Stimulation
REACT-NMES group: The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level. NMES will be delivered to the vastus lateralis synchronously with the perturbation, which will always occur 50 ms after slip-onset and last for 450 ms including the period between liftoff to touchdown of the first compensatory step.
BEHAVIORAL
Reactive balance training without Neuromuscular Electrical Stimulation
REACT group: The REACT group will undergo the same reactive balance training (in terms of type, dosage: intensity, frequency) as the REACT-NMES group. The only difference will be that the REACT group will receive ShamNMES for same time after the compensatory step touchdown. The ActiveStep treadmill will be used to deliver slips during all sessions. Each subject will experience three levels of perturbations over 12 sessions (24 slips/session) in progressive ascending way. On the first week, subjects will start with the lowest displacement level (6 cm) and move up to the next level (12 cm) by week 2 if they have \< 5 falls out of 8 slips at the previous level. By week 3, subjects are expected to move to level 3 (24 cm) and train at that for weeks 3 to 6. If subjects don't move up a level, training will continue at the lower level.
Primary outcome measures
Change in Falls
Time frame: Pre-training (during week 2 i.e., Session 2), Post-training (during week 9 i.e., Session 16)
A fall will be detected when the force exerted through the safety-harness load cell exceeds 30% of a person's body weight and verified with video analysis. Otherwise, the trial will be a balance recovery. Higher percentages indicate more falls.
Change in Reactive Stability
Time frame: Pre-training (during week 2 i.e., Session 2), Post-training (during week 9 i.e., Session 16)
Reactive stability (dimensionless) will be measured at the time point of compensatory limb touchdown after slipping. Stability will be calculated as the shortest distance from the COM state to the backward balance loss threshold. The instantaneous COM state is determined by its position and velocity (computed from filtered marker data) relative to the BOS, normalized respectively to foot length and the square root of the product of gravitational acceleration and body height. Higher values indicate better reactive stability.
Change in Proactive Stability
Time frame: Pre-training (during week 2 i.e., Session 2), Post-training (during week 9 i.e., Session 16)
Proactive stability (dimensionless) will be measured at the time point of slipping limb touchdown i.e., before slipping. Stability will be calculated as the shortest distance from the COM state to the backward balance loss threshold. The instantaneous COM state is determined by its position and velocity (computed from filtered marker data) relative to the BOS, normalized respectively to foot length and the square root of the product of gravitational acceleration and body height. Higher values indicate better proactive stability.
Change in Vertical Limb support
Time frame: Pre-training (during week 2 i.e., Session 2), Post-training (during week 9 i.e., Session 16)
Vertical limb support (dimensionless) is quantified by the quotient of hip vertical velocity to its height (VZhip/ Zhip). Zhip will be obtained as the vertical distance of the bilateral hip midpoint to the surface of the platform and its vertical velocity (VZhip), as the first-order differentiation of hip height. Its positive direction is upward. Higher values indicate better vertical limb support.
Change in Muscle synergies
Time frame: Pre-training (during week 2 i.e., Session 2), Post-training (during week 9 i.e., Session 16)
To assess the muscular synergies, electromyography sensors will be applied to four muscle groups on both lower limbs. The muscle groups include tibialis anterior, gastrocnemius, quadriceps and hamstring group of muscles. Higher values indicate more muscle synergies.
Change in Perturbation-evoked potentials
Time frame: Pre-training (during week 2 i.e., Session 2), Post-training (during week 9 i.e., Session 16)
Data from different midline electroencephalographic (EEG) channels overlying lower limb frontal, sensorimotor and parietal regions will be used to extract the perturbation-evoked potentials (P1, N1, P2 and N2) to assess their spatio-temporal parameter (amplitude: microvolts, latency: seconds)
Change in time-frequency power
Time frame: Pre-training (during week 2 i.e., Session 2), Post-training (during week 9 i.e., Session 16)
Data from different midline electroencephalographic channels overlying lower limb frontal, sensorimotor, and parietal regions will be used to extract the alpha, beta, theta, and gamma power (decibels). Higher values indicate more frequency power.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Age group: 18-90 years.
- Presence of hemiparesis.
- Onset of stroke (\> 6 months).
- Ability to walk at least for 2 minutes on the treadmill with or without ankle foot orthosis.
- Can understand and communicate in English.
- Cognitively and behaviorally capable of complying with the regimen (Mini-Mental State Examination \> 25/30).
- No history or recent use (i.e., past 6 weeks) of any Neuromuscular electrical stimulation device to leg muscles during walking (e.g., Bioness, Walkaide).
Exclusion criteria
- Subjects will not proceed with the test if any of the following occurs at baseline measurement: 1) HR \> 85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \> 165 mmHg and/or diastolic blood pressure (DBP) \> 110 mmHg during rest, or 3) oxygen saturation (measured by pulse oximeter) \< 95% during rest.
- Body weight of more than 250 lbs.
- Spasticity (Ashworth scale \> 2).
- Loss of protective sensations on the paretic leg (indicated by inability to perceive the 5.07/10 g on Semmes-Weinstein Monofilament) or inability to feel the NMES.
- Severe osteoporosis (indicated by T score \< -2)
- Cognitive impairment (indicated by Mini-Mental State Exam score\<25)
- Global Aphasia (indicated by \<71% on the Mississippi Aphasia Screening Test).
- Subjects with Chedoke McMaster Leg Assessment Scale score (\> 4).
Where
- Chicago, Illinois
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 7, 2026 · Source of record for eligibility and locations